Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: Mutations occur early and persist throughout tumor progression

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3468-3474

  Omholt, Katarina ^a   Karsberg, Sofia ^a   Platz, Anton ^a   Kanter, Lena ^a   Ringborg, Ulrik ^a   Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER INVASION; CODON; CONTROLLED STUDY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; AGED; DISEASE COURSE; DNA SEQUENCE; FEMALE; GENETICS; GENOTYPE; MALE; MIDDLE AGED; MUTATION; ONCOGENE RAS; ONSET AGE; PATHOLOGY; REGRESSION ANALYSIS; SKIN TUMOR; ULTRAVIOLET RADIATION;

AGE OF ONSET; AGED; CODON; DISEASE PROGRESSION; FEMALE; GENES, RAS; GENOTYPE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; REGRESSION ANALYSIS; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 0036850146     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Clark, W. H., Jr., Elder, D. E., Guerry, D., IV, Epstein, M. N., Greene, M. H., and Van Horn, M. A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol., 15: 1147-1158, 1984.
2. Joneson, T., and Bar-Sagi, D. Ras effectors and their role in mitogenesis and oncogenesis. J. Mol. Med., 75: 587-593, 1997.
3. Bos, J. L. ras oncogenes in human cancer: A review. Cancer Res., 49: 4682-4689, 1989.
4. H genes mutated at codon 61. Cell, 44: 167-176, 1986.
5. Trahey, M., and McCormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science (Wash. DC), 238: 542-545, 1987.
6. ras with GAP, exchange factors, and its biological effector target. J. Biol. Chem., 268: 9157-9160, 1993.
7. Raybaud, F., Noguchi, T., Marics, I., Adelaide, J., Planche, J., Batoz, M., Aubert, C., de Lapeyriere, O., and Birnbaum, D. Detection of a low frequency of activated ras genes in human melanomas using a tumorigenicity assay. Cancer Res., 48: 950-953, 1988.
8. Van't Veer, L. J., Burgering, B. M. T., Versteeg, R., Boot, A. J. M., Ruiter, D. J., Osanto, S., Schrier, P. I., and Bos, J. L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol., 9: 3114-3116, 1989.
9. Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon-Cardo, C., McNutt, N. S., Bressler, J., and Andreeff, M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: Correlation of point mutations with differentiation phenotype. Oncogene, 4: 1363-1374, 1989.
10. Shukla, V. K., Hughes, D. C., Hughes, L. E., McCormick, F., and Padua, R. ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res., 5: 121-127, 1989.
11. Ball, N. J., Yohn, J. J., Morelli, J. G., Norris, D. A., Golitz, L. E., and Hoeffler, J. P. RAS mutations in human melanoma: A marker of malignant progression. J. Investig. Dermatol., 102: 285-290, 1994.
12. Carr, J., and Mackie, R. M. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol., 131: 72-77, 1994.
13. Platz, A., Ringborg, U., Månsson Brahme, E., and Lagerlöf, B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res., 4: 169-177, 1994.
14. Jafari, M., Papp, T., Kirchner, S., Diener, U., Henschler, D., Burg, G., and Schiffmann, D. Analysis of ras mutations in human melanocytic lesions: Activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol., 121: 23-30, 1995.
15. 1 checkpoint control are frequently mutated in human melanoma metastases. Br. J. Cancer, 74: 936-941, 1996.
16. van Elsas, A., Zerp, S. F., van der Flier, S., Krüse, K. M., Aarnoudse, C., Hayward, N. K., Ruiter, D. J., and Schrier, P. I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol., 149: 883-893, 1996.
17. Jiveskog, S., Ragnarsson-Olding, B., Platz, A., and Ringborg, U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Investig. Dermatol., 111: 757-761, 1998.
18. Demunter, A., Ahmadian, M. R., Libbrecht, L., Stas, M., Baens, M., Scheffzek, K., Degreef, H., De Wolf-Peeters, C., and van den Oord, J. J. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res., 61: 4916-4922, 2001.
19. Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., and van den Oord, J. J. Analysis of N- and K-Ras mutations in the distinctive tumor progression phases of melanoma. J. Investig Dermatol., 117: 1483-1489, 2001.
20. Van der Lubbe, J. L. M., Rosdorff, H. J. M., Bos, J. L., and Van der Eb, A. J. Activation of N-ras induced by ultraviolet irradiation in vitro. Oncogene Res., 3: 9-20, 1988.
21. Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., II, and DePinho, R. A. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev., 11: 2822-2834, 1997.
22. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., Horner, J. W., II, Cordon-Cardo, C., Yancopoulos, G. D., and DePinho, R. A. Essential role for oncogenic Ras in tumour maintenance. Nature (Lond.), 400: 468-472, 1999.
23. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
24. Hunger, R. E., Brand, C. U., Streit, M., Eriksen, J. A., Gjertsen, M. K., Saeterdal, I., Braathen, L. R., and Gaudernack G. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol., 10: 161-167, 2001.
25. Jansen, B., Schlagbauer-Wadl, H., Kahr, H., Heere-Ress, E., Mayer, B. X., Eichler, H. G., Pehamberger, H., Gana-Weisz, M., Ben-David, E., Kloog, Y., and Wolff, K. Novel Ras antagonist blocks human melanoma growth. Proc. Natl. Acad. Sci. USA, 96: 14019-14024, 1999.
26. Rowinsky, E. K., Windle, J. J., and Von Hoff, D. D. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J. Clin. Oncol., 17: 3631-3652, 1999.